These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

112 related articles for article (PubMed ID: 207051)

  • 41. The use of a multicomponent standard for clostridial vaccines.
    Gray AK
    Dev Biol Stand; 1976; 32():245-50. PubMed ID: 187507
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Immunobiology of Clostridium perfringens type A: passive protection of NMRI mice. Western blot analysis of immunoreactive polypeptides.
    Traub WH; Bauer D; Wolf U
    Chemotherapy; 1991; 37(5):318-26. PubMed ID: 1804593
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Selective and differential medium for detecting Clostridium botulinum.
    Silas JC; Carpenter JA; Hamdy MK; Harrison MA
    Appl Environ Microbiol; 1985 Oct; 50(4):1110-1. PubMed ID: 2867740
    [TBL] [Abstract][Full Text] [Related]  

  • 44. [Use of the passive hemagglutination inhibition reaction for the purpose of determining the antigenic activity of anatoxins in vitro].
    Vorontsov IV; Moshiashvili IIa; Severtsova MK; Besova SA
    Zh Mikrobiol Epidemiol Immunobiol; 1979 Apr; (4):62-6. PubMed ID: 375637
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Antigenic relationships among the proteolytic and nonproteolytic strains of Clostridium botulinum.
    Solomon HM; Lynt RK; Kautter DA; Lilly T
    Appl Microbiol; 1971 Feb; 21(2):295-9. PubMed ID: 4927406
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Quantitative assay of diphtherial toxin and of immunologically cross-reacting proteins by reversed passive hemagglutination.
    Holmes RK; Perlow RB
    Infect Immun; 1975 Dec; 12(6):1392-400. PubMed ID: 54339
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Proteases of Clostridium botulinum. V. Studies on the serological relationship between proteases from Clostridium botulinum and other spore-forming bacteria.
    Tjaberg TB; Fossum K
    Acta Vet Scand; 1973 May; 14(5):700-11. PubMed ID: 4359093
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Immunofluorescent study of the spore antigens of proteolytic strains of Clostridium botulinum.
    Princewill TJ
    J Hyg (Lond); 1979 Aug; 83(1):1-9. PubMed ID: 379206
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Serological studies of Clostridium botulinum type E and related organisms.
    Lynt RK; Solomon HM; Kautter DA; Lilly T
    J Bacteriol; 1967 Jan; 93(1):27-35. PubMed ID: 5335894
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Detection of Clostridium botulinum type G toxin by enzyme-linked immunosorbent assay.
    Lewis GE; Kulinski SS; Reichard DW; Metzger JF
    Appl Environ Microbiol; 1981 Dec; 42(6):1018-22. PubMed ID: 7316509
    [TBL] [Abstract][Full Text] [Related]  

  • 51. [Isolation and immunochemical study of the toxic complex of Cl. botulinum type F].
    Blagoveshchenskiĭ VA; Nikitina AA; Khatuntseva NV; Mironova MV; Mikheeva GV
    Zh Mikrobiol Epidemiol Immunobiol; 1979 Dec; (12):28-32. PubMed ID: 117654
    [TBL] [Abstract][Full Text] [Related]  

  • 52. [Method of obtaining an erythrocyte diagnosticum for detecting Cl. perfringens type A enterotoxin].
    Bakulin IN; Kashkina GB; Sergeeva TI
    Zh Mikrobiol Epidemiol Immunobiol; 1982; (11):79-82. PubMed ID: 6297189
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Antitoxin response in cattle vaccinated with Clostridium perfringens type C toxoid.
    Kennedy KK; Norris SJ; Beckenhauer WH; White RG
    Vet Med Small Anim Clin; 1977 Jul; 72(7):1213-5. PubMed ID: 196381
    [No Abstract]   [Full Text] [Related]  

  • 54. [Complementation of theta-and kappa-toxin production between two group mutants of Clostridium perfringens (author's transl)].
    Higashi Y
    Tanpakushitsu Kakusan Koso; 1976 Nov; Suppl():160-3. PubMed ID: 194281
    [No Abstract]   [Full Text] [Related]  

  • 55. Serological specificity of type E botulinal toxin.
    Johnson HM; Smith BG; Lewis KH
    Proc Soc Exp Biol Med; 1971 Jul; 137(3):973-6. PubMed ID: 4997865
    [No Abstract]   [Full Text] [Related]  

  • 56. [Hemagglutinin specificity of Cl. botulinum types A, B, and F in reaction with erythrocytes of various animals].
    Blagoveshchenskii BA; Ivanova LG; Khatuntseva NV; Kliucheva VV; Nikitina AA
    Zh Mikrobiol Epidemiol Immunobiol; 1975 Jul; (7):47-51. PubMed ID: 56111
    [TBL] [Abstract][Full Text] [Related]  

  • 57. [Microcirculatory changes following the combined action of the toxin of C1. perfringens type A and biological products of C1. butyricum].
    Tselukh AV; Donskikh EA; Shtefan EE; Shtykhno IuM
    Biull Eksp Biol Med; 1977 Nov; 84(11):552-4. PubMed ID: 201314
    [No Abstract]   [Full Text] [Related]  

  • 58. Partial characterization of the enzymatic activity associated with the binary toxin (type C2) produced by Clostridium botulinum.
    Simpson LL; Zepeda H; Ohishi I
    Infect Immun; 1988 Jan; 56(1):24-7. PubMed ID: 3121511
    [TBL] [Abstract][Full Text] [Related]  

  • 59. A Clostridium botulinum type B vaccine for prevention of shaker foal syndrome.
    Thomas RJ; Rosenthal DV; Rogers RJ
    Aust Vet J; 1988 Mar; 65(3):78-80. PubMed ID: 3041951
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Successful immunization of mink with a toxoid against Clostridium botulinum, type C.
    LARSEN AE; NICHOLES PS; GEBHARDT LP
    Am J Vet Res; 1955 Oct; 16(61 Part 1):573-5. PubMed ID: 13259039
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.